{"title":"PCR靶向16S rRNA、cfb和hylB检测妊娠35 ~ 37周妇女B组链球菌","authors":"Juan Liu, Jun Yan, Juan Lv","doi":"10.1080/17520363.2025.2496132","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Polymerase chain reaction (PCR) is a rapid molecular technique for pathogen detection, but its application in detecting group B Streptococcus (GBS) requires further exploration. This study assessed the diagnostic performance of the PCR method for GBS detection in pregnant women with 35 to 37 weeks of pregnancy.</p><p><strong>Methods: </strong>This study enrolled 116 women at 35-37 weeks of pregnancy and simultaneously collected two vaginal swab samples for GBS detection via culture and PCR methods.</p><p><strong>Results: </strong>Through the culture method, 21 (18.1%) samples were positive for GBS. Moreover, 24 (20.7%), 23 (19.8%), and 23 (19.8%) samples were positive for GBS according to PCR methods targeting 16S rRNA, cfb, and hylB, respectively. The results of PCR-based GBS detection of 16S rRNA (Kappa value = 0.917, <i>p</i> < 0.01), cfb (Kappa value = 0.944, <i>p</i> < 0.01), and hylB (Kappa value = 0.944, <i>p</i> < 0.01) were consistent with those of the culture method. The sensitivity and specificity were 1.000 and 0.968 for the PCR method targeting 16S rRNA, 1.000 and 0.979 for cfb, and 1.000 and 0.979 for hylB, respectively.</p><p><strong>Conclusion: </strong>PCR targeting 16S rRNA, <i>cfb</i>, and <i>hylB</i> may serve as a reliable diagnostic method for GBS detection in women with 35 to 37 weeks of pregnancy.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":"19 10","pages":"379-384"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077469/pdf/","citationCount":"0","resultStr":"{\"title\":\"PCR targeting 16S rRNA, <i>cfb</i>, and <i>hylB</i> for group B Streptococcus detection in women with 35 to 37 weeks of pregnancy.\",\"authors\":\"Juan Liu, Jun Yan, Juan Lv\",\"doi\":\"10.1080/17520363.2025.2496132\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Polymerase chain reaction (PCR) is a rapid molecular technique for pathogen detection, but its application in detecting group B Streptococcus (GBS) requires further exploration. This study assessed the diagnostic performance of the PCR method for GBS detection in pregnant women with 35 to 37 weeks of pregnancy.</p><p><strong>Methods: </strong>This study enrolled 116 women at 35-37 weeks of pregnancy and simultaneously collected two vaginal swab samples for GBS detection via culture and PCR methods.</p><p><strong>Results: </strong>Through the culture method, 21 (18.1%) samples were positive for GBS. Moreover, 24 (20.7%), 23 (19.8%), and 23 (19.8%) samples were positive for GBS according to PCR methods targeting 16S rRNA, cfb, and hylB, respectively. The results of PCR-based GBS detection of 16S rRNA (Kappa value = 0.917, <i>p</i> < 0.01), cfb (Kappa value = 0.944, <i>p</i> < 0.01), and hylB (Kappa value = 0.944, <i>p</i> < 0.01) were consistent with those of the culture method. The sensitivity and specificity were 1.000 and 0.968 for the PCR method targeting 16S rRNA, 1.000 and 0.979 for cfb, and 1.000 and 0.979 for hylB, respectively.</p><p><strong>Conclusion: </strong>PCR targeting 16S rRNA, <i>cfb</i>, and <i>hylB</i> may serve as a reliable diagnostic method for GBS detection in women with 35 to 37 weeks of pregnancy.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\"19 10\",\"pages\":\"379-384\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077469/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2496132\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2496132","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
PCR targeting 16S rRNA, cfb, and hylB for group B Streptococcus detection in women with 35 to 37 weeks of pregnancy.
Aims: Polymerase chain reaction (PCR) is a rapid molecular technique for pathogen detection, but its application in detecting group B Streptococcus (GBS) requires further exploration. This study assessed the diagnostic performance of the PCR method for GBS detection in pregnant women with 35 to 37 weeks of pregnancy.
Methods: This study enrolled 116 women at 35-37 weeks of pregnancy and simultaneously collected two vaginal swab samples for GBS detection via culture and PCR methods.
Results: Through the culture method, 21 (18.1%) samples were positive for GBS. Moreover, 24 (20.7%), 23 (19.8%), and 23 (19.8%) samples were positive for GBS according to PCR methods targeting 16S rRNA, cfb, and hylB, respectively. The results of PCR-based GBS detection of 16S rRNA (Kappa value = 0.917, p < 0.01), cfb (Kappa value = 0.944, p < 0.01), and hylB (Kappa value = 0.944, p < 0.01) were consistent with those of the culture method. The sensitivity and specificity were 1.000 and 0.968 for the PCR method targeting 16S rRNA, 1.000 and 0.979 for cfb, and 1.000 and 0.979 for hylB, respectively.
Conclusion: PCR targeting 16S rRNA, cfb, and hylB may serve as a reliable diagnostic method for GBS detection in women with 35 to 37 weeks of pregnancy.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
